[1][2] His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews.
[3][4][5][6] He has been a top executive at several pharmaceutical companies,[7] with respect to the development and clinical testing of novel anticancer drugs and cell therapies.
[8][9] For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013.
[19] His research partly focused on the dysregulation of the nuclear factor NF-κB pathway in inflammation, autoimmunity, immunodeficiency, and neoplasia, and the options for its therapeutic targeting.
[25] He is a member of the Board of Directors at Damon Runyon Cancer Research Foundation,[26] Alkermes PLC,[27] Infinity Pharmaceuticals,[28] and Zai Labs.